IL2 and nonpapillary renal cell carcinoma: Other therapies, including immunotherapy with interleukin-2 (IL-2) or interferon alpha (IFNα), have been demonstrated low efficiency because of systemic toxicities during ccRCC treatment.3, 4, 5 Therefore, further discoveries of effective therapeutic targets and drugs are paramount to improve the prognosis of ccRCC patients.